Ethical concerns in schizophrenia research: Looking back and moving forward

Schizophrenia Bulletin

Volumn 32, Issue 1, 2006, Pages 30-36

  Wilson, Scott T ^a,b   Stanley, Barbara ^a,b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL TRIAL; COGNITION; DRUG WITHDRAWAL; ETHICS; GENETICS; HUMAN; INFORMED CONSENT; MEDICAL RESEARCH; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHIATRY; RELIABILITY; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SUICIDAL BEHAVIOR; VALIDATION PROCESS;

BIOMEDICAL RESEARCH; CLINICAL PROTOCOLS; FORECASTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFORMED CONSENT; MENTAL HEALTH SERVICES; PATIENT SELECTION; SCHIZOPHRENIA;

EID: 30344449158     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbj023     Document Type: Review

References (76)

1. Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law No. 10, Nuremberg, October 1946-April 1947, vol. 2. Washington, DC: Government Printing Office; 1949.
2. World Medical Association. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 2000;227:925-926.
3. Romano J. Reflections on informed consent. Arch Gen Psychiatry 1974;30:129-135.
4. American Psychiatric Association. The principles of medical ethics with annotations especially applicable to psychiatry. Arlington, VA: American Psychiatric Publishing; 1973.
5. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Washington, DC: Government Printing Office; 1979.
6. Research involving persons with mental disorders that may affect decision-making capacity. Rockville, MD: National Bioethics Advisory Commission; 1998.
7. Michels R. Are research ethics bad for our mental health? N Engl J Med 1999;340:1427-1430.
8. Stanley BH, Stanley M. Psychiatric patients in research: protecting their autonomy. Compr Psychiatry 1981;22:420-427.
9. Stone AA. Informed consent: special problems for psychiatry. Hosp Communit Psychiat 1979;30:321.
10. Katz J. Disclosure and consent in psychiatric practice: mission impossible? In: Hoffer A, ed. Law and ethics in the practice of psychiatry. New York, NY: Spectrum Publications; 1981:91.
11. Benson PR, Roth LH, Winslade WJ. Informed consent in psychiatric research: preliminary findings from an ongoing investigation. Social Science & Medicine 1985;20:1331-1341.
12. Irwin M, Lovitz A, Marder SR, Mintz J, Winslade WJ, Van Putten T, Mills MJ. Psychotic patients' understanding of informed consent. Am J Psychiatry 1985;142:1351-1354.
13. Grossman L, Summers F. A study of the capacity of schizophrenic patients to give informed consent. Hospital and Community Psychiatry 1980;31:205-206.
14. Stanley B, Stanley M, Lautin A, Kane J, Schwartz N. Preliminary findings of psychiatric patients as research participants: a population at risk? Am J Psychiatry 1981;138:669-671.
15. Meisel A, Roth LH. What we do and do not know about informed consent. JAMA 1981;246:2473-2477.
16. Wirshing DA, Wirshing WC, Marder SR, Liberman RP, Mintz J. Informed consent: assessment of comprehension. Am J Psychiatry 1998;155:1508-1511.
17. Carpenter WT, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS. Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry 2000;57:533-538.
18. Palmer BW, Dunn LB, Appelbaum PS, Jeste DV. Correlates of treatment-related decision-making capacity among middle-aged and older patients with schizophrenia. Arch Gen Psychiatry 2004;61:230-236.
19. Moser DJ, Schultz SK, Arndt S, et al. Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry 2002;159:1201-1207.
20. Koren D, Poyurovsky M, Seidman LJ, Goldsmith M, Wenger S, Klein EM. The neuropsychological basis of competence to consent in first-episode schizophrenia: a pilot metacognitive study. Biol Psychiatry 2005;57:609-616.
21. Stanley B, Stanley M, Peselow E, et al. The effects of psychotropic drugs on informed consent. Psychopharmacol Bull 1982;18:102-104.
22. Stanley B, Stanley M, Stein J, Guido L, Transit RP. Psychopharmacologic treatment and informed consent: empirical research. Psychopharmacol Bull 1985;21:110-113.
23. Dunn LB, Lindamer LA, Palmer BW, Schneiderman LJ, Jeste DV. Enhancing comprehension of consent for research in older patients with psychosis: a randomized study of a novel consent procedure. Am J Psychiatry 2001;158:1911-1913.
24. Appelbaum PS, Grisso T. The MacArthur treatment competence study: I. Mental illness and competence to consent to treatment. Law and Human Behavior 1995;19:105-126.
25. Zapt PA, Roesch R. An investigation of the construct of competence: a comparision of the FIT, the MacCAT-CA, and the MacCAT-T. Law and Human Behavior 2005;29:229-252.
26. Grisso T, Appelbaum PS, Hill-Fotouhi C. The MacCAT-T: a clinical tool to assess patients' capacities to make treatment decisions. Psychiatric Services 1997;48:1415-1419.
27. Appelbaum PS, Grisso T. The MacArthur Competence Assessment Tool - clinical research. Sarasota: Professional Resources Press; 1996.
28. Sturman ED. The capacity to consent to treatment and research: a review of standardized assessment tools. Clin Psychol Rev 2005: In press.
29. Harkavy-Friedman J, Restifo K, Malapsina D, et al. Suicidal behavior in schizophrenia: characteristics of those who had and had not attempted suicide. Am J Psychiat 1999;156:1276-1278.
30. Pearson JL, Stanley B, King CA, Fisher CB. Intervention research with persons at high risk for suicidality: safety and ethical implications. J Clin Psychiatry 2001;62(Supp25):17-26.
31. US Public Health Service. The surgeon general's call to action to prevent suicide. Washington, DC; 1999.
32. US Public Health Service. National strategy for suicide prevention: goals and objectives for action. Rockville, MD; 2001.
33. Institute of Medicine of the National Academies. Reducing suicide: a national imperative. Committee on Pathophysiology and Prevention of Adolescent and Adult Suicide. Washington, D.C.: The National Academies Press; 2002.
34. Evern C, Evren B. Characteristics of schizophrenic patients with a history of a suicide attempt. Int J of Psy Clin Prac 2004;227-234.
35. Markman M. The needs of science versus the needs of patients: ethical concerns in cancer clinical trials. Cleve Clin J Med 2003;1008-1015.
36. Griffiths RD, Nee PA. Ethical considerations in accident and emergency research. Emerg Med J 2002;19:423-427.
37. Biros MH, Runge JW, Lewis RJ, Doherty C. Emergency medicine and the development of the Food and Drug Administration's final rule on informed consent and waiver of informed consent in emergency research circumstances. Acad Emerg Med 1998;5:359-368.
38. Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997;54:401-407.
39. Fins JJ. The call of the sirens: navigating the ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997;54:415-416.
40. Volavka J. Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? Arch Gen Psychiatry 1998;55:280-281.
41. Baldessarini RJ, Viguera AC. Medication removal and research in psychotic disorders. Arch Gen Psychiatry 1998;55:281-282.
42. Carpenter WT, Appelbaum PS, Levine RJ. The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry 2003;160:356-363.
43. Kim SYH. Benefits and burdens of placebos in psychiatric research. Psychopharmacology 2003;171:13-18.
44. Roberts LW, Warner TD, Nguyen KP, Geppert CMA, Rogers MK, Roberts BB. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom reemergence during psychopharmacological research participation. Psychopharmacology 2003;171:58-67.
45. Food and Drug Administration. International conference on harmonization E10: choice of control group and related issues in clinical trials. Federal Register 2001;66:24390-24391.
46. Roberts LW, Warner TD, Nguyen K, Geppert CMA, Rogers MK, Roberts BR. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology 2003;171:58-67.
47. Moser DJ, Reese RL, Schultz SK, Benjamin ML, Arndt S, Fleming FW, Andreasen NC. Informed consent in medication-free schizophrenia research. Am J Psychiatry 2005;162:1209-1211.
48. Wyatt RJ, Henter ID, Bartko JJ. The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry 1999;46:1092-1105.
49. Tirupati NS, Rangaswamy T, Raman P. Duration of untreated psychosis and treatment outcome in schizophrenia patients untreated for many years. Aust N Z J Psychiatry 2004;38:339-343.
50. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996;22:241-256.
51. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351.
52. Birchwood M, Macmillam F. Early intervention in schizophrenia. Aust N Z J Psychiatry 1993;27:374-378.
53. Carpenter WT, Heinrichs DW. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 1983;9:533-542.
54. Herz MI, Glazer W, Mirza M, Mostert M, et al. Treating prodromal episodes to prevent relapse in schizophrenia. Br J Psychiatry 1989;155:123-127.
55. Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry: Journal for the Study of Interpersonal Processes 1992;55:4-15.
56. Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr Res 1997;28:207-222.
57. Gaebel W, Frick U, Kopcke W, Linden M, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 1993;163:8-12.
58. Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 1995;38:1-3.
59. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22:201-222.
60. Falloon RH, Kydd RR, Coverdale JH, Laidlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 1996;22:271-282.
61. Vaglum P. Earlier detection and intervention in schizophrenia: unsolved questions. Schizophr Bull 1996;22:347-351.
62. Larsen TK, Opjordsmoen S. Early identification and treatment of schizophrenia: conceptual and ethical considerations. Psychiatry: Interpersonal & Biological Processes 1996;59:371-380.
63. Corcoran C, Malespina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk." Schizophr Res 2005;73:173-184.
64. Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkotter J. Pharmacological interventions in the initial prodromal phase of psychosis. Eur Psychiatry 2005;20:1-6.
65. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res 2001;51:47-54.
66. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001;51:31-38.
67. Yung AR, McGorry PD. The prodromal phase of first episode psychosis: past and current conceptualizations. Schizophr Bull 1996;22:353-370.
68. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003;29:703-715.
69. Post SG. Preventing schizophrenia and Alzheimer's disease: comparative ethics. Schizophr Res 2001;51:103-108.
70. McGlashan TH, Zipursky RB, Perkins D, Addington J, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophr Res 2003;61:7-18.
71. Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed consent in early psychosis research: National Institute of Mental Health Workshop, November 15, 2000. Schizophr Bull 2001;27:571-584.
72. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-1192.
73. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004;9:14-27.
74. Dinwiddie SH, Hoop J, Gershon ES. Ethical issues in the use of genetic information. Int Rev Psychiatry 2003;16:320-328.
75. Biesecker BH, Peay HL. Ethical issues in psychiatric genetics research: points to consider. Psychopharm 2003;171:27-35.
76. Appelbaum PS. Ethical issues in psychiatric genetics. J Psychiatr Res 2004;10:343-351.